What is HC Wainwright’s Forecast for ATNM FY2028 Earnings?

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) – Analysts at HC Wainwright raised their FY2028 earnings per share estimates for shares of Actinium Pharmaceuticals in a research note issued on Wednesday, June 3rd. HC Wainwright analyst J. Pantginis now anticipates that the company will earn ($0.69) per share for the year, up from their previous estimate of ($0.86). The consensus estimate for Actinium Pharmaceuticals’ current full-year earnings is ($1.41) per share.

Separately, Stephens reissued an “overweight” rating and issued a $5.00 target price on shares of Actinium Pharmaceuticals in a research report on Tuesday, March 31st. Two investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $4.50.

Actinium Pharmaceuticals Stock Performance

Shares of NYSE:ATNM opened at $1.11 on Friday. Actinium Pharmaceuticals has a 52-week low of $0.95 and a 52-week high of $1.95. The firm has a market capitalization of $34.83 million, a P/E ratio of -0.80 and a beta of -0.06. The stock has a 50 day moving average price of $1.19 and a 200-day moving average price of $1.26.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. AM Investment Strategies LLC bought a new position in Actinium Pharmaceuticals during the 4th quarter valued at approximately $40,000. Qube Research & Technologies Ltd bought a new position in Actinium Pharmaceuticals during the 2nd quarter valued at approximately $70,000. Bank of America Corp DE increased its position in Actinium Pharmaceuticals by 76.6% during the 4th quarter. Bank of America Corp DE now owns 78,767 shares of the company’s stock valued at $99,000 after buying an additional 34,176 shares in the last quarter. Renaissance Technologies LLC increased its position in Actinium Pharmaceuticals by 35.4% during the 4th quarter. Renaissance Technologies LLC now owns 390,784 shares of the company’s stock valued at $531,000 after buying an additional 102,154 shares in the last quarter. Finally, Vanguard Group Inc. increased its position in Actinium Pharmaceuticals by 0.9% during the 3rd quarter. Vanguard Group Inc. now owns 1,384,543 shares of the company’s stock valued at $2,215,000 after buying an additional 12,703 shares in the last quarter. Institutional investors own 27.50% of the company’s stock.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on the development of targeted radiopharmaceutical therapies for patients with hematologic malignancies. The company’s proprietary technology platform combines monoclonal antibodies with radioisotopes to deliver highly potent, cell‐killing radiation directly to cancer cells while sparing healthy tissues. Actinium’s lead product candidate, Iomab‐B, is being evaluated as a conditioning regimen for older patients with acute myeloid leukemia (AML) who are ineligible for standard bone marrow transplants.

In addition to Iomab‐B, Actinium’s pipeline includes Actimab‐A, an anti‐CD33 antibody labeled with the radioisotope bismuth‐213 for the treatment of relapsed or refractory AML.